More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...

As amyloid immunotherapy enters clinical care in more countries, providers the world over are eager for more information on how well it works, and especially how safe it is. To collect such data in ...

Even as two amyloid immunotherapies are in clinical use, scientists still have many questions about how these antibodies affect the brain. Neuropathology and biomarker data from treated patients are ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...

Many people with Alzheimer’s notice their sense of smell isn’t as sharp as it used to be long before their memory declines. The underlying mechanisms responsible for this change have remained a ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Cerebrospinal fluid and plasma markers are now being used to help diagnose Alzheimer’s in memory clinics, but what about using them to stage the disease? That’s the next big step, said Henrik ...

Tau PET correlates closely with cognitive decline in Alzheimer’s disease, making it a potential surrogate outcome measure. Yet in amyloid immunotherapy trials to date, this signal has not always ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma ...